BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9009097)

  • 1. Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridization compared with RT-PCR.
    Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; Langenhuijsen MM; Ossenkoppele GJ
    Leukemia; 1997 Feb; 11(2):301-5. PubMed ID: 9009097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
    Diamond J; Goldman JM; Melo JV
    Blood; 1995 Apr; 85(8):2171-5. PubMed ID: 7718887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia.
    Thijsen SF; van Oostveen JW; Schuurhuis GJ; Theijsmeijer AP; Oudejans CB; van Wijk IJ; Langenhuijsen MM; Ossenkoppele GJ
    Leukemia; 1997 Oct; 11(10):1762-8. PubMed ID: 9324298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobilization of hematopoietic progenitors in patients with chronic myeloid leukemia.
    Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; Niewint AW; Ossenkoppele GJ
    Bone Marrow Transplant; 1997 Nov; 20(10):835-42. PubMed ID: 9404923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
    Tbakhi A; Pettay J; Sreenan JJ; Abdel-Razeq H; Kalaycio M; Hoeltge G; Miller ML; Tubbs RR
    Am J Clin Pathol; 1998 Jan; 109(1):16-23. PubMed ID: 9426513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells.
    Savoldo B; Sammarelli G; Dotti G; Garau D; Regazzi E; Cilloni D; Tabilio A; Rizzoli V; Carlo-Stella C
    Leukemia; 1998 Mar; 12(3):434-40. PubMed ID: 9529140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
    Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
    Leukemia; 2002 Jan; 16(1):53-9. PubMed ID: 11840263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCR.
    Keil F; Mitterbauer G; Chen X; Haas OA; Kalhs P; Lechner K; Mannhalter C; Moser K; Worel N; Pirc-Danoewinata H; Louda N; Loidolt H; Rabitsch W; Greinix HT
    Transfusion; 2001 Jan; 41(1):111-6. PubMed ID: 11161255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
    Grand FH; Chase A; Iqbal S; Nguyen DX; Lewis JL; Marley SB; Davidson RJ; Goldman JM; Gordon MY
    Genes Chromosomes Cancer; 1998 Oct; 23(2):109-15. PubMed ID: 9739013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
    Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
    Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation at single cell level of residual Philadelphia negative hemopoietic stem cells in chronic phase CML patients.
    Akel S; Kolialexi A; Mavrou A; Metaxotou C; Loukopoulos D; Yataganas X
    Cancer Genet Cytogenet; 2000 Oct; 122(2):93-100. PubMed ID: 11106818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
    Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.